ENB-003
- Generic Name
- ENB-003
- Drug Type
- Small Molecule
- Background
ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Phase 2
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 60
- Registration Number
- NCT04918186
- Locations
- 🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- MelanomaOvary CancerCancerPancreatic CancerSolid Tumor
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- ENB Therapeutics, Inc
- Target Recruit Count
- 137
- Registration Number
- NCT04205227
- Locations
- 🇦🇺
Kinghorn-St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Blacktown Oncology, Blacktown, New South Wales, Australia
🇺🇸Cedars Sinai-The Angeles Clinic, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath